Stylus Medicine launches with big pharma funding

Cambridge, USA-based biotech Stylus Medicine, which says it is dedicated to developing transformative in vivo genetic medicines, today emerged from stealth with $85 million in financing.

Stylus’ funding includes a $45 million Series A extension financing with participation from RA Capital Management, Khosla Ventures, and six new investors including Chugai Venture Fund, Eli Lilly (NYSE: LLY), and Johnson & Johnson Innovation – JJDC. This financing follows a $40 million Series A investment from founding investors RA Capital and Khosla Ventures.

Stylus explained that it will use this financing to advance its in vivo genetic medicines platform and pipeline of in vivo therapeutic programs. The company’s powerful and elegant engineering platform combines sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. The platform is based on Stylus-designed therapeutic-grade recombinases capable of encoding polyfunctional multi-kb payloads with high efficiency, high specificity, and high fidelity. This system enables durable, flexible, and scalable in vivo cell engineering, overcoming major limitations of ex vivo cell therapy manufacturing and expanding the reach of transformative genetic medicines.